Sep 17, 2026 08:30AM
Sep 17, 2026 08:30AM
Sep 1, 2026 08:03AM
Sep 1, 2026 08:00AM
Jul 10, 2026 08:02AM
Jul 10, 2026 08:00AM
Jul 6, 2026 09:00AM MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
Jun 17, 2026 08:00AM
Jun 17, 2026 08:00AM
Jun 4, 2026 08:02AM
Jun 4, 2026 08:00AM
May 27, 2026 08:00AM
May 27, 2026 08:00AM
May 14, 2026 08:01AM MIRA Pharmaceuticals reports positive Phase 1 results for Ketamir-2
May 14, 2026 08:00AM
May 13, 2026 08:04AM
May 13, 2026 08:00AM
Mar 4, 2026 08:00AM
Mar 4, 2026 08:00AM
Feb 3, 2026 07:31AM
Feb 3, 2026 07:30AM MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study
Oct 24, 2025 07:30AM
Oct 24, 2025 07:30AM
Sep 16, 2025 07:30AM
Sep 16, 2025 07:30AM
Aug 19, 2025 08:30AM
Aug 19, 2025 08:30AM
Aug 12, 2025 08:32AM MIRA's Ketamir-2 study accepted for publication in peer-reviewed journal
Aug 12, 2025 08:30AM
Jul 30, 2025 07:30AM
Jul 30, 2025 07:30AM
Jul 29, 2025 07:31AM
Jul 29, 2025 07:30AM
May 6, 2025 08:02AM
May 6, 2025 08:00AM MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
Apr 23, 2025 08:04AM
Apr 23, 2025 08:00AM
Apr 16, 2025 08:03AM
Apr 16, 2025 08:00AM
Apr 1, 2025 08:00AM
Mar 24, 2025 07:33AM
Mar 24, 2025 07:30AM MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
Mar 13, 2025 08:00AM
Mar 4, 2025 08:02AM
Mar 4, 2025 08:00AM
Dec 19, 2024 09:02AM
Dec 19, 2024 09:00AM
Dec 10, 2024 08:34AM
Dec 10, 2024 08:30AM MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Oct 28, 2024 07:41AM

334,273 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All